FIELD: medicine, peptides, biochemistry, pharmacy.
SUBSTANCE: invention relates to modification of glycosylation of proteins for preparing polypeptides with improved therapeutic indices including antibodies with enhanced antibody-dependent cellular cytotoxicity. For preparing indicated polypeptides cell-host is used that is modified with nucleic acid encoding enzyme β-1,4-N-acetylglucosaminyltransferase III (GnTIII). Prepared polypeptide represents, in particular, IgG or its fragment. Invention discloses a method for preparing polypeptide and antibodies or its fragment and a fusion protein prepared by indicated method. Invention describes a pharmaceutical composition used for increasing Fc-mediated cellular cytotoxicity and comprising antibody and carrier, and its using in cancer treatment, and a method for treatment of disease associated with elevated amount or production of B cells using indicated antibody, in particular, against CD20, and representing antibody IDEC-C2B8 in the preferable variant. Invention provides preparing polypeptide and antibody possessing the enhanced Fc-mediated cellular cytotoxicity that decrease the content of B cells in a patient body.
EFFECT: improved preparing method, valuable medicinal properties of polypeptide and antibodies.
38 cl, 21 dwg, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| FUSION CONSTRUCTS AND THEIR APPLICATION TO CREATE ANTIBODIES WITH HIGH FC RECEPTOR BINDING AFFINITY AND WITH EFFECTOR FUNCTION | 2010 |
|
RU2623167C2 |
| METHOD FOR PREPARING ANTIBODIES HAVING IMPROVED PROPERTIES | 2011 |
|
RU2604811C2 |
| METHOD OF DESTROYING CELLS USING EFFECTOR FUNCTIONS OF ANTI-EphA4 ANTIBODIES | 2007 |
|
RU2429246C2 |
| ANTIGEN-BINDING MOLECULES, WHICH BIND EGFR, VECTORS CODING THEM AND USE THEREOF | 2013 |
|
RU2610688C2 |
| ANTIBODIES AGAINST A2 TENASTIN-C AND METHODS FOR USE THEREOF | 2011 |
|
RU2584597C2 |
| METHODS AND COMPOSITIONS FOR IMPROVING EFFECTIVENESS OF ANTIBODY FOR MEDICAL APPLICATION WITH USING COMPOUNDS POTENTIATING NK-CELLS | 2004 |
|
RU2396981C2 |
| MODIFIED ANTIGEN-BINDING MOLECULES WITH CHANGED CELL SIGNAL ACTIVITY | 2006 |
|
RU2547931C2 |
| MONOCLONAL ANTIBODY OR ITS ANTIGEN-BINDING FRAGMENT WHICH SPECIFICALLY BINDS TO GD2 (GD2 GANGLIOSIDE) AND ITS USE | 2021 |
|
RU2796937C2 |
| NOVEL ANTI-IL13 ANTIBODIES AND USE THEREOF | 2004 |
|
RU2487887C2 |
| TREATMENT OF B-CELLULAR MALIGNANT TUMORS USING ANTI-CD40L ANTIBODIES IN COMBINATION WITH ANTI-CD20 ANTIBODIES AND/OR BY CHEMOTHERAPY AND RADIOTHERAPY | 2000 |
|
RU2305561C2 |
